Abstract
We evaluated the efficacy and tolerability of chemotherapy in HIV-infected patients with diffuse large B-cell lymphoma (DLBCL) receiving CHOP ± R (n = 17) or Burkitt lymphoma (BL) receiving CODOX-M/IVAC ± R (n = 15). The study was conducted in Beijing Ditan Hospital from January 2009 to August 2015. The following grade 4 adverse effects were observed in BL and DLBCL patients, respectively: neutropenia (80% versus 47.1%), anaemia (46.7% versus 5.9%), thrombocytopenia (53.3% versus 11.8%), bacterial pneumonia (33.3% versus 5.9%), and sepsis (20% versus 5.9%) (p < 0.05). In the BL group, 10 (66.7%) patients died from treatment-related or tumour-related causes, 5 (33.3%) achieved complete response, 1 achieved partial response (6.7%), and 7 developed progressive disease. The 1-year overall survival and progression-free survival rates were 33.3%. Of the DLBCL patients, 3 (17.6%) died from treatment-related causes, 14 (82.4%) achieved complete response, and 3 had progressive disease. The 1-year overall survival and progression-free survival rates were 82.4%. The strongest risk factor for death was relapse between chemotherapy cycles (adjusted hazard ratio = 47.3; 95%CI, 4.2-528.6, p = 0.002). Initiating antiretroviral therapy before c...Continue Reading
References
Nov 24, 1999·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·B D ChesonG P Canellos
Aug 16, 2002·Annals of Oncology : Official Journal of the European Society for Medical Oncology·G M MeadUNKNOWN UKLG LY06 collaborators
Sep 25, 2003·Blood·Christine P HansWing C Chan
May 26, 2005·Blood·Lawrence D KaplanDavid T Scadden
Dec 28, 2007·Blood·Lloyd T LamLouis M Staudt
Dec 17, 2008·Blood·Naoko AsanoShigeo Nakamura
Feb 23, 2011·Annals of Oncology : Official Journal of the European Society for Medical Oncology·J A BarnesJ S Abramson
Aug 30, 2011·Critical Care : the Official Journal of the Critical Care Forum·Hou-Hsien ChiangChong-Jen Yu
Dec 23, 2011·Advances in Hematology·J A RodrigoH A Leitch
Feb 9, 2012·British Journal of Haematology·Josep-Maria RiberaEvarist Feliu
Mar 28, 2012·Leukemia & Lymphoma·Fernando CabanillasMargarita Bruno
Mar 1, 2013·Annals of Oncology : Official Journal of the European Society for Medical Oncology·T WästerlidM Jerkeman
Mar 2, 2013·Blood·Shimin HuKen H Young
Jun 12, 2013·Haematologica·Tamara IntermesoliRenato Bassan
Jun 28, 2013·British Journal of Haematology·Fredrick HagemeisterFernando Cabanillas
Nov 10, 2013·PloS One·Jiang XiaoHongxin Zhao
Nov 15, 2013·The New England Journal of Medicine·Kieron DunleavyWyndham H Wilson
Dec 18, 2013·International Journal of Hematology·Shojiro InanoNobuyoshi Arima
Jan 15, 2014·AIDS·Rita CoutinhoMark Bower
May 10, 2015·Blood·Ariela NoyUNKNOWN AIDS Malignancy Consortium
Mar 15, 2016·AIDS Research and Human Retroviruses·Jiang XiaoHongxin Zhao
Jul 16, 2016·Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology·Nadia HowladerEric A Engels
Jul 1, 2013·Annals of Oncology : Official Journal of the European Society for Medical Oncology·T WästerlidM Jerkeman
Citations
Dec 20, 2017·International Reviews of Immunology·Omid RezahosseiniNima Rezaei
Mar 31, 2019·Scientific Reports·Dedong WuShuang Hu
Feb 3, 2021·Current HIV/AIDS Reports·Michalina A MontañoRachel A Bender Ignacio